# Cinnagen clinical trials: 21 on ClinicalTrials.gov (2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 21 trials with Cinnagen as lead sponsor, 0 of them recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Clinical trials led by Cinnagen: 21 rows for $5, every trial on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email.

Buy: https://specstream.ai/data/clinical-trials/company/cinnagen

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 21
- Recruiting or not yet: 0
- Read on: November 19, 2026

## Trials

The 21 newest of 21, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| December 4, 2025 | NCT07262762 | Spartina® (Tirzepatide) Effectiveness and Safety Evaluation | Cinnagen | Observational | Completed | Obesity & Overweight | 175 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07262762) |
| May 9, 2024 | NCT06406153 | Efficacy and Safety of YW17 (Laronidase-CinnaGen) Compared to Aldurazyme® in MPS I Patients | Cinnagen | Phase 3 | Completed | Mucopolysaccharidosis Type 1 | 12 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06406153) |
| April 14, 2023 | NCT05813470 | Efficacy and Safety of Zerafil® (Omalizumab) in Participants With Uncontrolled Moderate to Severe Allergic Asthma | Cinnagen | Phase 3 | Completed | Allergic Asthma, Uncontrolled Moderate to Severe | 256 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05813470) |
| October 19, 2022 | NCT05587062 | Efficacy and Safety of Aflibercept in Patients With Neovascular Age-related Macular Degeneration | Cinnagen | Phase 3 | Completed | Age-Related Macular Degeneration, Neovascular Age-related Macular Degeneration | 168 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05587062) |
| March 17, 2022 | NCT05285384 | Immunogenicity and Safety of a Booster Dose of the SpikoGen Vaccine in Kidney Transplant Recipients After Two Doses of Sinopharm Vaccine | Cinnagen | Not applicable | Completed | COVID-19 | 43 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05285384) |
| February 16, 2022 | NCT05242133 | Efficacy and Safety of Peginterferon Beta-1a (CinnaGen) in Participants With Relapsing Remitting Multiple Sclerosis | Cinnagen | Phase 3 | Completed | Relapsing Remitting Multiple Sclerosis (RRMS) | 168 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05242133) |
| February 9, 2022 | NCT05231590 | Immunogenicity and Safety of the SpikoGen COVID-19 Vaccine in Children Aged 5 to \<12 Years and 12 to \<18 Years Compared With Adults Aged 18... | Cinnagen | Phase 3 | Completed | COVID-19 | 581 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05231590) |
| January 4, 2022 | NCT05175625 | Immunogenicity and Safety of a Booster Dose of the SpikoGen COVID-19 Vaccine | Cinnagen | Phase 3 | Completed | COVID-19 | 300 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05175625) |
| August 13, 2021 | NCT05005559 | Phase III Clinical Trial of CinnaGen COVID-19 Vaccine (SpikoGen) | Cinnagen | Phase 3 | Completed | Covid19 | 16,876 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05005559) |
| July 19, 2021 | NCT04966338 | Efficacy and Safety of Xacrel® (Ocrelizumab) in Participants With Relapsing Remitting Multiple Sclerosis | Cinnagen | Phase 3 | Completed | Multiple Sclerosis, Relapsing-Remitting | 170 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04966338) |
| July 12, 2021 | NCT04957212 | Comparing Efficacy and Safety Between Pertuzumab® and Perjeta® in Neoadjuvant Treatment of HER2+ Breast Cancer | Cinnagen | Phase 3 | Completed | HER2-positive Breast Cancer | 214 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04957212) |
| June 29, 2021 | NCT04944368 | Phase II Clinical Trial of CinnaGen COVID-19 Vaccine (SpikoGen) | Cinnagen | Phase 2 | Completed | Covid19 | 400 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04944368) |
| June 16, 2021 | NCT04928313 | Safety and Effectiveness of Cinnomer® (Glatiramer Acetate) in Multiple Sclerosis (MS) Treatment in Iran | Cinnagen | Observational | Completed | Relapsing Multiple Sclerosis | 368 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04928313) |
| July 7, 2020 | NCT04460079 | Safety and Effectiveness Assessment of PeGagen® (Pegfilgrastim) in the Prevention of Chemotherapy-induced FN | Cinnagen | Observational | Completed | Chemotherapy-induced Neutropenia | 654 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04460079) |
| August 3, 2018 | NCT03614715 | Pharmacokinetics and Pharmacodynamics of CinnoVex (Interferon Beta-1a) Compared to Avonex (Interferon Beta-1a) | Cinnagen | Phase 1 | Completed | Bioequivalence, Healthy | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03614715) |
| February 5, 2018 | NCT03421119 | Comparing Efficacy and Safety of CinnaGen-liraglutide Versus Victoza® in Patients With Type II Diabetes | Cinnagen | Phase 3 | Unknown | Diabetes Mellitus, Type 2 | 300 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03421119) |
| January 24, 2018 | NCT03408639 | Comparing Efficacy and Safety of CinnaGen Beta Erythropoietin (CinnaPoietin®) Versus Eprex® on the Treatment of Anemia in ESRD Hemodialysis... | Cinnagen | Phase 3 | Completed | Anemia in End-Stage Renal Disease | 156 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03408639) |
| January 5, 2018 | NCT03391934 | Comparing Efficacy and Safety of Cetuximab (CinnaGen) Versus Erbitux® (Merck) in Metastatic Colorectal Cancer | Cinnagen | Phase 3 | Unknown | Metastatic Colorectal Cancer | 234 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03391934) |
| September 6, 2017 | NCT03273192 | A Study Of CinnoRA (Adalimumab-CinnaGen) And Adalimumab (Humira) In Healthy Subjects | Cinnagen | Phase 1 | Completed | Bioequivalence, Phase 1 | 74 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03273192) |
| July 19, 2017 | NCT03223025 | Comparing Efficacy and Safety of CinnaGen Biosimilar Growth Hormone (CinnaTropin®) Versus Nordilet in Children With Idiopathic Growth... | Cinnagen | Phase 3 | Completed | Idiopathic Growth Hormone Deficiency | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03223025) |
| June 1, 2017 | NCT03172325 | Study to Demonstrate Non-Inferior Efficacy and Safety of CinnoRA® Versus Humira® for Treatment of Active RA | Cinnagen | Phase 3 | Completed | Active Rheumatoid Arthritis | 136 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03172325) |

## By phase

| Phase | Trials |
| --- | --- |
| Phase 1 | 2 |
| Phase 2 | 1 |
| Phase 3 | 14 |
| Not applicable | 1 |
| Observational | 3 |

## By status

| Status | Trials |
| --- | --- |
| Completed | 19 |
| Unknown | 2 |

## Conditions

| Condition group | Trials |
| --- | --- |
| COVID-19 | 5 |
| Multiple Sclerosis | 2 |
| Macular Degeneration | 1 |
| Mucopolysaccharidosis I | 1 |
| Obesity | 1 |
| Overweight | 1 |
| Colorectal Neoplasms | 1 |
| Multiple Sclerosis, Relapsing-Remitting | 1 |
| Kidney Failure, Chronic | 1 |
| Anemia | 1 |
| Febrile Neutropenia | 1 |
| Recurrence | 1 |
| Diabetes Mellitus, Type 2 | 1 |
| Asthma | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Plastics companies in the United States](https://specstream.ai/data/businesses/plastics-companies/united-states)
- [French restaurants in the United States](https://specstream.ai/data/businesses/french-restaurants/united-states)
- [B2B oil refinery companies in the United States](https://specstream.ai/data/businesses/b2b-oil-refinery-companies/united-states)
- [Ramen restaurants in the United States](https://specstream.ai/data/businesses/ramen-restaurants/united-states)
- [Home network installers in the United States](https://specstream.ai/data/businesses/home-network-installers/united-states)
- [Breakfast and brunch restaurants in the United States](https://specstream.ai/data/businesses/breakfast-and-brunch-restaurants/united-states)
